• Pre-eclampsia screening of
    5000 European women in 5 countries

  • Novel metabolomics and proteomics biomarkers
    to detect pre-eclampsia and improve pregnancy outcomes

  • An effective screening test has the potential for
    significant health and economic impact


IMPROvED recruitment has began  at EMC, Rotterdam

1st patient recruited at Erasmus MC, Rotterdam

Congratulations! The first participant enrolled in the IMPROvED clinical study at the Dutch recruitment center, Erasmus MC, Rotterdam. IMPROvED recruitment of low-risk first-time mums has now began in the Netherlands.

Please contact us by
phone: +31640160455
e-mail: improved@erasmusmc.nl


Participant recruitment commences at Keele University

IMPROvED is now recruiting low risk first time mums in Keele, UK!

Please contact us by
phone: 07548190954 or 01782672123
e-mail: Louise Wood or Tracey Harrison

Metabolomic Diagnostics Logo

Metabolomic Diagnostics Completes €0.75 Million Investment Round

We are pleased to announce that IMPROvED Partner Metabolomic Diagnostics has secured €750,000 in venture funding through a syndicate of investors including SOSventures Ireland Fund, AIB Seed Capital Fund and Enterprise Ireland.   
Metabolomic Diagnostic’s innovative solution has the potential to revolutionise pre-natal care with its breakthrough blood test “PrePsia” for early detection of women at high risk of developing pre-eclampsia during their pregnancy.